BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to partic ...

Core Insights - aTyr Pharma, Inc. is presenting preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the AACR Annual Meeting 2025, indicating progress in its clinical development [1][2] Group 1: Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][4] - The company's lead therapeutic candidate is efzofitimod, which is in clinical development for treating interstitial lung disease [4] Group 2: Research Findings - ATYR2810 has shown potential in combating drug resistance mechanisms in aggressive cancers like glioblastoma multiforme (GBM) [2][3] - Preclinical research indicates that ATYR2810 enhances anti-tumor immunity and significantly increases overall survival when used as a single agent [3] - The combination of ATYR2810 with anti-PD-1 therapies further improves survival rates and reduces tumor size in GBM models [3]

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage therapy NT219, which targets tumor immune evasion and drug resistance, with promising data presented at the AACR 2025 Annual Meeting [1][3][10] Group 1: NT219 Overview - NT219 is a novel dual inhibitor of IRS1/2 and STAT3, currently in a Phase 2 study for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in combination with pembrolizumab and cetuximab [2][10] - The mechanism of NT219 involves suppression of STAT3 and degradation of IRS1/2, which blocks IGF1R/IRS and downstream AKT and β-catenin signaling pathways [3][7] Group 2: Clinical Data and Biomarkers - Significant upregulation of STAT3, IRS1/2, and β-catenin was observed in HNSCC tumors compared to normal tissues, indicating potential biomarkers for NT219-based therapy [3][7] - The data suggest that activated forms of STAT3 and IGF1R correlate with patient response to NT219 treatment, supporting their role as potential biomarkers [7][12] Group 3: Efficacy in Colorectal Cancer - NT219 has shown anti-tumor efficacy in colorectal cancer (CRC) models, with APC-loss and activated β-catenin identified as potential biomarkers for treatment response [5][12] - The therapy has demonstrated the ability to reverse chemo-resistance and enhance the efficacy of existing chemotherapy regimens [12] Group 4: Future Directions - The findings from the AACR meeting are expected to guide study design, patient selection, and combination therapy strategies for NT219 [3][7] - Purple Biotech is committed to advancing NT219 in collaboration with the University of Colorado for R/M HNSCC patients [10]

SHELTON, Conn., April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its "reasonable best efforts" public offering with participation from certain new and existing institutional and accredited investors ...

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Executive Chairman Ashley Cordova - CEO Christoph Brackmann - CFO Frank Leonard - EVP and President, NovoCure Oncology Nicolas Leupin - CMO Conference Call Participants Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Vijay Kumar - Evercore ISI Jessica Fye - JPMorgan Emily Bodnar - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome ...

WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present updated data from its ongoing Phase 2 clinical trial investigating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) at ...

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team partici ...

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team partici ...

Core Insights - The study identifies IRS2 as a significant driver of brain metastasis in colorectal cancer, suggesting that targeting IRS2 with NT219 may provide a new therapeutic strategy [1][2][4] - The combination of NT219 and 5-fluorouracil (5-FU) has been shown to inhibit the formation of colorectal cancer brain metastasis and extend survival in preclinical models [2][5] - Approximately 20% of colorectal cancer patients present with distant metastasis at diagnosis, with an additional 50% developing metastasis later, highlighting the potential impact of NT219 on patient outcomes [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes NT219, CM24, and CAPTN-3 [7] - NT219 is a novel small molecule designed to degrade IRS1/2 and block downstream signaling pathways, currently advancing into a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [1][7] - The company aims to leverage NT219's unique mechanism of action to expand clinical development opportunities in colorectal cancer and other malignancies [2][7] Research Findings - The study analyzed over 35,000 colorectal cancer samples, revealing a distinct genomic profile associated with brain metastasis and highlighting the role of IRS2 in this process [4] - Elevated IRS2 expression is linked to the promotion of brain metastasis through modulation of the β-catenin pathway and oxidative phosphorylation [4][5] - The findings support the potential of NT219 as a therapeutic strategy against colorectal cancer brain metastasis, offering new avenues for treatment [5]

Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [2] - The company's oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications [2] Pipeline Details - CM24 is a humanized monoclonal antibody that blocks CEACAM1, demonstrating improvement in a Phase 2 study for pancreatic ductal adenocarcinoma when combined with nivolumab and chemotherapy [2] - NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in a Phase 1 study and advancing to a Phase 2 study in collaboration with the University of Colorado [2] - CAPTN-3 is a preclinical platform of conditionally activated tri-specific antibodies designed to induce a strong immune response within the tumor microenvironment [2] Upcoming Events - The CEO of Purple Biotech, Gil Efron, will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025 [1]